MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple Turns 50: From Garage Startup to AI Crossroads 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
